Biofil Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals' board approved its Q1 FY26 (quarter ended June 30, 2025) unaudited results. Revenue from operations fell to ₹643.26 lakhs from ₹844.34 lakhs a year ago, but net profit jumped sharply to ₹241.10 lakhs (₹1.48 EPS) versus ₹16.93 lakhs (₹0.10 EPS) last year. The profit surge was driven mainly by other income of ₹283.20 lakhs, arising from the disposal of the company's undertaking at Sanwer Road, Indore. The Pharma division revenue declined to ₹484.75 lakhs while the Chemicals division grew to ₹158.51 lakhs. The board also approved the appointment of Joshi Sahay & Company as Secretarial Auditors for five years, re-appointed two independent directors for their second and final terms, elevated Whole-Time Director Mr. Ketan Shah to Chairman and Managing Director for three years, approved shifting the registered office within Indore effective September 1, 2025, and fixed the 40th AGM for September 27, 2025 via video conferencing.
The headline profit growth looks impressive but is largely a one-time gain from the sale of the Indore property rather than core business strength, since core revenue actually shrank. Shareholders should watch whether the Pharma division can recover in coming quarters, as it remains the larger segment. Governance changes such as the CMD elevation and auditor appointment are routine and neutral for the stock.